CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques.

ABSTRACT: CRANAD-28, a difluoroboron curcumin analogue, has been demonstrated in earlier reports to successfully label amyloid beta (A?) plaques for imaging both ex vivo and in vivo. CRANAD-28's imaging brightness, ability to penetrate the blood brain barrier, and low toxicity make the compound a potentially potent imaging tool in Alzheimer's research. In this study, the A?-labeling ability of CRANAD-28 was investigated in further detail using histological staining to assess different criteria, including stained A? plaque brightness, A? plaque size, and A? plaque number count. The results of this study demonstrated CRANAD-28 to be superior across all criteria assessed. Furthermore, CRANAD-28 and IBA-1 antibody were used to label A?-plaques and microglia respectively. Statistical analysis with Spearman regression revealed a statistically significant negative correlation between the size of labeled A? plaques and surrounding microglia density. This finding provides interesting insight into A? plaque and microglia dynamism in AD pathology and corroborates the findings of previous studies. In addition, we found that CRANAD-28 provided distinct spectral signatures for A?s in the core and periphery of the plaques. Based on the study's results, CRANAD-28 could be considered as an alternative standard for imaging A?-plaques in future research studies.

SUBMITTER: Ran K 

PROVIDER: S-EPMC7070309 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature